John Sourbeer
Stock Analyst at UBS
(0.70)
# 3,851
Out of 4,876 analysts
37
Total ratings
36.84%
Success rate
-25.23%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $10 → $11 | $7.41 | +48.45% | 6 | Apr 1, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $24.64 | -4.63% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $28.87 | +55.87% | 3 | Feb 13, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $50 → $48 | $47.77 | +0.48% | 4 | Feb 7, 2025 | |
| WST West Pharmaceutical Services | Upgrades: Buy | $350 → $390 | $218.87 | +78.19% | 3 | Dec 12, 2024 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.29 | +55.04% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $94.79 | +52.97% | 3 | Nov 5, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $310.69 | +54.49% | 4 | Mar 8, 2024 | |
| AKYA Akoya Biosciences | Maintains: Buy | $7 → $7.5 | $1.24 | +504.84% | 2 | Mar 5, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $41.80 | +144.02% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $11.73 | +326.26% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $270 | $144.56 | +86.77% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $134.38 | -4.75% | 2 | Jul 27, 2022 |
Cryoport
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $11
Current: $7.41
Upside: +48.45%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $24.64
Upside: -4.63%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $28.87
Upside: +55.87%
Qiagen
Feb 7, 2025
Maintains: Neutral
Price Target: $50 → $48
Current: $47.77
Upside: +0.48%
West Pharmaceutical Services
Dec 12, 2024
Upgrades: Buy
Price Target: $350 → $390
Current: $218.87
Upside: +78.19%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.29
Upside: +55.04%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $94.79
Upside: +52.97%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $310.69
Upside: +54.49%
Akoya Biosciences
Mar 5, 2024
Maintains: Buy
Price Target: $7 → $7.5
Current: $1.24
Upside: +504.84%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $41.80
Upside: +144.02%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $11.73
Upside: +326.26%
Sep 7, 2022
Initiates: Buy
Price Target: $270
Current: $144.56
Upside: +86.77%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $134.38
Upside: -4.75%